Plasma pharmacokinetics of tigolaner, emodepside, and praziquantel following topical administration of a combination product (Felpreva®) and of intravenous administration of the individual active ingredients in cats

IF 1.7 Q3 PARASITOLOGY
Norbert Mencke , Wolfgang Bäumer , Kristine Fraatz , Ralph Krebber , Marc Schneider , Katrin Blazejak
{"title":"Plasma pharmacokinetics of tigolaner, emodepside, and praziquantel following topical administration of a combination product (Felpreva®) and of intravenous administration of the individual active ingredients in cats","authors":"Norbert Mencke ,&nbsp;Wolfgang Bäumer ,&nbsp;Kristine Fraatz ,&nbsp;Ralph Krebber ,&nbsp;Marc Schneider ,&nbsp;Katrin Blazejak","doi":"10.1016/j.crpvbd.2023.100126","DOIUrl":null,"url":null,"abstract":"<div><p>Felpreva® for cats contains the new acaricidal/insecticidal active ingredient tigolaner in a fixed combination with the nematocidal and cestocidal compounds emodepside and praziquantel, respectively. The plasma pharmacokinetics of tigolaner, emodepside, and praziquantel were evaluated in clinically healthy cats following topical (spot-on) treatment as fixed combination Felpreva®. For the determination of bioavailability intravenous administration of single active ingredients was also performed. After a single topical administration of Felpreva® using the target dose volume of 0.148 ​ml/kg to cats, tigolaner reached mean peak concentrations of 1352 ​μg/l with a T<sub>max</sub> of 12 days and a mean half-life of 24 days. Simulation of repetitive topical administration every 91 days indicates only a low risk of accumulation after reaching steady state within two to three administrations. The volume of distribution calculated after intravenous dosing was 4 ​l/kg and plasma clearance was low with 0.005 ​l/h/kg. Overall plasma exposure was 1566 ​mg∗h/l after topical administration, providing an absolute bioavailability of 57%. Tigolaner was mainly cleared <em>via</em> the faeces (54% within 28 days), renal clearance was neglectable (&lt; 0.5% within 28 days). Emodepside and praziquantel showed mean peak concentrations of 44 ​μg/l and 48 ​μg/l (reached after 1.5 days and 5 ​h, respectively). Overall plasma exposures were 20.6 and 3.69 ​mg∗h/l, respectively. The elimination half-life was 14.5 days for emodepside and 10 days for praziquantel after topical administration. After topical administration of Felpreva® using 2.5× and 5× dose multiples an almost proportional increase of plasma exposure was observed for all three active ingredients. With the addition of tigolaner, Felpreva® combines the established pharmacokinetic (PK) characteristics of emodepside and praziquantel contained in Profender® spot-on for cats with the favourable PK of tigolaner suitable for a 3-months protection against fleas and ticks.</p></div>","PeriodicalId":94311,"journal":{"name":"Current research in parasitology & vector-borne diseases","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344656/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current research in parasitology & vector-borne diseases","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667114X23000146","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PARASITOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Felpreva® for cats contains the new acaricidal/insecticidal active ingredient tigolaner in a fixed combination with the nematocidal and cestocidal compounds emodepside and praziquantel, respectively. The plasma pharmacokinetics of tigolaner, emodepside, and praziquantel were evaluated in clinically healthy cats following topical (spot-on) treatment as fixed combination Felpreva®. For the determination of bioavailability intravenous administration of single active ingredients was also performed. After a single topical administration of Felpreva® using the target dose volume of 0.148 ​ml/kg to cats, tigolaner reached mean peak concentrations of 1352 ​μg/l with a Tmax of 12 days and a mean half-life of 24 days. Simulation of repetitive topical administration every 91 days indicates only a low risk of accumulation after reaching steady state within two to three administrations. The volume of distribution calculated after intravenous dosing was 4 ​l/kg and plasma clearance was low with 0.005 ​l/h/kg. Overall plasma exposure was 1566 ​mg∗h/l after topical administration, providing an absolute bioavailability of 57%. Tigolaner was mainly cleared via the faeces (54% within 28 days), renal clearance was neglectable (< 0.5% within 28 days). Emodepside and praziquantel showed mean peak concentrations of 44 ​μg/l and 48 ​μg/l (reached after 1.5 days and 5 ​h, respectively). Overall plasma exposures were 20.6 and 3.69 ​mg∗h/l, respectively. The elimination half-life was 14.5 days for emodepside and 10 days for praziquantel after topical administration. After topical administration of Felpreva® using 2.5× and 5× dose multiples an almost proportional increase of plasma exposure was observed for all three active ingredients. With the addition of tigolaner, Felpreva® combines the established pharmacokinetic (PK) characteristics of emodepside and praziquantel contained in Profender® spot-on for cats with the favourable PK of tigolaner suitable for a 3-months protection against fleas and ticks.

Abstract Image

局部给药组合产品(Felpreva®)和单独活性成分静脉给药后替戈兰那、emodepside和吡喹酮在猫体内的血浆药代动力学
猫用Felpreva®含有新的杀螨/杀虫活性成分替戈兰,分别与杀线虫剂和杀螨剂化合物依莫地肽和吡喹酮固定组合。在作为固定组合Felpreva®进行局部(现场)治疗后,对临床健康猫的替戈拉纳、依莫地肽和吡喹酮的血浆药代动力学进行了评估。为了测定生物利用度,还进行了单一活性成分的静脉给药。使用0.148的目标剂量体积单次局部给药Felpreva®后​对猫来说,替戈拉纳达到了1352的平均峰值浓度​μg/l,Tmax为12天,平均半衰期为24天。模拟每91天重复局部给药表明,在两到三次给药内达到稳定状态后,积聚的风险很低。静脉给药后计算的分布体积为4​l/kg,血浆清除率低至0.005​l/h/kg。总的血浆暴露量为1566​局部给药后,提供57%的绝对生物利用度。提戈拉纳主要通过粪便清除(28天内清除54%),肾脏清除率可忽略不计(28天以内<0.5%)。埃莫迪肽和吡喹酮的平均峰值浓度为44​μg/l和48​μg/l(1.5天后和5天后达到​h、 分别)。总体血浆暴露量分别为20.6和3.69​毫克*小时/升。局部给药后,依莫司肽和吡喹酮的消除半衰期分别为14.5天和10天。使用2.5倍和5倍剂量倍数局部给药Felpreva®后,观察到所有三种活性成分的血浆暴露量几乎成比例增加。通过添加替戈拉纳,Felpreva®结合了Profender®斑点猫中所含的依莫司肽和吡喹酮的既定药代动力学(PK)特征,以及适用于3个月防跳蚤和蜱虫的替戈拉内的良好PK。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.60
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信